Inventor · disambiguated record
Matthew William Burnell Trotter
Also filed as: TROTTER MATTHEW · TROTTER MATTHEW WILLIAM BURNELL
4 granted patents·7 pending applications·18 citations·filing 2013–2021
72Inventor score
Top patents by PatentIndex Score
11 records- 0190US10018637B2Methods for treating inflammatory and other diseases and the use of biomarkers as predictors of clinical sensitivity to treatment with apremilastCELGENE INT II SARL·Filed 2016·Granted Jul 10, 2018·7 cites·19 claims
- 0289US10996215B2Methods for determining drug efficacy for the treatment of diffuse large B-cell lymphoma, multiple myeloma, and myeloid cancersCELGENE CORP·Filed 2018·Granted May 4, 2021·5 cites·21 claims
- 0383US10689708B2Methods for treating diffuse large B-cell lymphoma and the use of biomarkers as a predictor of responsiveness to drugsCELGENE CORP·Filed 2016·Granted Jun 23, 2020·3 cites·11 claims
- 0478US10604738B2Transcription factor mediated programming towards megakaryocytesCAMBRIDGE ENTPR LTD·Filed 2013·Granted Mar 31, 2020·3 cites·15 claims
- 0567US2022003749A1Methods for determining drug efficacy for the treatment of diffuse large b-cell lymphoma, multiple myeloma, and myeloid cancersCELGENE CORP·Filed 2021·Application pending·0 cites
- 0654US2020255804A1Transcription Factor Mediated Programming Towards MegakaryocytesCAMBRIDGE ENTPR LTD·Filed 2020·Application pending·0 cites
- 0754US2016313300A1Methods for determining drug efficacy for the treatment of diffuse large b-cell lymphoma, multiple myeloma, and myeloid cancersCELGENE CORP·Filed 2014·Application pending·0 cites
- 0852US2021102257A1Methods for treating diffuse large b-cell lymphoma and the use of biomarkers as a predictor to responsiveness to drugsCELGENE CORP·Filed 2020·Application pending·0 cites
- 0941US2016312292A1Methods for treating hematological cancers and the use of biomarkers as a predictor of clinical sensitivity to immunodulatory therapiesCELGENE CORP·Filed 2014·Application pending·0 cites
- 1036US2017038387A1Methods for treating chronic lymphocytic leukemia and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapiesCELGENE CORP·Filed 2016·Application pending·0 cites
- 1136US2018238886A1Methods for treating hematological cancer and the use of biomarkers as a predictor for responsiveness to treatment compoundsCELGENE CORP·Filed 2018·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Matthew William Burnell Trotter files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →